{
  "data": [
    {
      "product": "argx-113",
      "indication": "bp",
      "study": "argx-113-2009",
      "sdtm_ae_refresh_date": "2024-07-13",
      "adsl_refresh_date": "2024-07-13",
      "Trial_Title": "A PHASE 2/3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF EFGARTIGIMOD PH20 SC IN ADULT PARTICIPANTS WITH BULLOUS PEMPHIGOID",
      "No_of_subjects_treated": 98,
      "First_ICF_date": "2022-06-22",
      "eosdt": "2024-07-11",
      "lstcndt": "2024-07-11",
      "FPFV": "2022-06-09",
      "LPLV": "2024-07-11",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.5",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-2009",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 2,
      "days_since_last_ae_refresh": 2,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": "2024-07-11",
      "EDC_extract_min_dt": "2024-07-11"
    },
    {
      "product": "argx-113",
      "indication": "bp",
      "study": "argx-113-2010",
      "sdtm_ae_refresh_date": "2024-07-09",
      "adsl_refresh_date": "2024-07-09",
      "Trial_Title": "AN OPEN-LABEL EXTENSION STUDY OF ARGX-113-2009 TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD PH20 SC IN ADULT PARTICIPANTS WITH BULLOUS PEMPHIGOID",
      "No_of_subjects_treated": 33,
      "First_ICF_date": "2023-03-22",
      "eosdt": "2024-07-01",
      "lstcndt": "2024-07-03",
      "FPFV": "2022-02-21",
      "LPLV": "2024-07-03",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "1",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2010",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 6,
      "days_since_last_ae_refresh": 6,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "cidp",
      "study": "argx-113-1902",
      "sdtm_ae_refresh_date": "2024-07-06",
      "adsl_refresh_date": "2024-07-06",
      "Trial_Title": "OPEN-LABEL EXTENSION OF THE ARGX-113-1802 TRIAL TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD PH20 SC IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)",
      "No_of_subjects_treated": 228,
      "First_ICF_date": "2020-09-17",
      "eosdt": "2024-06-12",
      "lstcndt": "2024-06-28",
      "FPFV": "2020-09-17",
      "LPLV": "2024-06-27",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-1902",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (ADHERE+)",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 9,
      "days_since_last_ae_refresh": 9,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-2201",
      "sdtm_ae_refresh_date": "2024-07-12",
      "adsl_refresh_date": "2024-07-13",
      "Trial_Title": "A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS OF EFGARTIGIMOD IV 10 MG/KG SINGLE DOSE ADMINISTERED IN PARTICIPANTS WITH RENAL IMPAIRMENT",
      "No_of_subjects_treated": 33,
      "First_ICF_date": "2023-07-19T08:50",
      "eosdt": "2024-04-29",
      "lstcndt": "2024-06-12",
      "FPFV": "2023-07-19",
      "LPLV": "2024-06-12",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2201",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A Phase 1, Open-label, Study to Evaluate the Pharmacokinetics of Efgartigimod IV 10 mg/kg Single Dose Administered in Participants With Renal Impairment",
      "status_ss": "startup",
      "days_since_last_adsl_refresh": 2,
      "days_since_last_ae_refresh": 3,
      "days_between": 1,
      "ord": 1,
      "ae_refresh_dt": "2024-05-18",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-2204",
      "sdtm_ae_refresh_date": "2024-02-20",
      "adsl_refresh_date": "2024-02-20",
      "Trial_Title": "A PHASE 1, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, SINGLE-DOSE, BIOEQUIVALENCE STUDY OF EFGARTIGIMOD PH20 SC ADMINISTERED VIA A PREFILLED SYRING VERSUS A VIAL + SYRINGE PRESENTATION IN HEALTHY ADULTS",
      "No_of_subjects_treated": 120,
      "First_ICF_date": "2023-03-02",
      "eosdt": "2023-06-30",
      "lstcndt": "2023-06-30",
      "FPFV": "2023-03-02",
      "LPLV": "2023-06-30",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "ACTIVE C49649",
      "STUDYID": "ARGX-113-2204",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A Phase 1, Randomized, Open-label, Parallel-Group, Single-Dose, Bioequivalence Study of Efgartigimod PH20 SC Administered via a Prefilled Syringe Versus a Vial-Syringe Presentation in Healthy Adults",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 146,
      "days_since_last_ae_refresh": 146,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-2303",
      "sdtm_ae_refresh_date": "2024-04-06",
      "adsl_refresh_date": "2024-04-08",
      "Trial_Title": "A PHASE 1, SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY IN HEALTHY ADULTS TO ASSESS THE FEASIBILITY OF DIFFERENT SPEEDS OF SUBCUTANEOUS INJECTION FOR EFGARTIGIMOD PH20 SC",
      "No_of_subjects_treated": 48,
      "First_ICF_date": "2023-08-16T09:17",
      "eosdt": "2023-12-06",
      "lstcndt": "2023-12-06",
      "FPFV": "2023-08-16",
      "LPLV": "2023-12-06",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.384",
      "Control_Type": "DOSE RESPONSE C120841",
      "STUDYID": "ARGX-113-2303",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A phase 1, single-center, randomized, open-label, crossover study in healthy adults to assess the feasibility of different speeds of subcutaneous injection for efgartigimod PH20 SC (formerly known as Autoinjector study)",
      "status_ss": "planning",
      "days_since_last_adsl_refresh": 98,
      "days_since_last_ae_refresh": 100,
      "days_between": 2,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-2312",
      "sdtm_ae_refresh_date": "2024-03-27",
      "adsl_refresh_date": "2024-03-28",
      "Trial_Title": "A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, 2-PERIOD CROSS-OVER, BIOEQUIVALENCE STUDY OF EFGARTIGIMOD PH20 SC ADMINSTERED VIA A PREFILLED SYRINGE VERSUS A VIAL + SYRINGE PRESENTATION IN HEALTHY PARTICIPANTS",
      "No_of_subjects_treated": 72,
      "First_ICF_date": "2023-10-21",
      "eosdt": "2024-02-12",
      "lstcndt": "2024-02-12",
      "FPFV": "2023-10-21",
      "LPLV": "2024-02-12",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "ACTIVE C49649",
      "STUDYID": "ARGX-113-2312",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "new phase 1 study (bioequivalence)",
      "status_ss": "planning",
      "days_since_last_adsl_refresh": 109,
      "days_since_last_ae_refresh": 110,
      "days_between": 1,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "iim",
      "study": "argx-113-2007",
      "sdtm_ae_refresh_date": "2024-06-04",
      "adsl_refresh_date": "2024-07-10",
      "Trial_Title": "A PHASE 2/3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 2-ARM, MULTICENTER, OPERATIONALLY SEAMLESS STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACODYNAMICS,",
      "No_of_subjects_treated": 102,
      "First_ICF_date": "2022-11-29",
      "eosdt": "2024-05-22",
      "lstcndt": "2024-05-28",
      "FPFV": "2022-08-22",
      "LPLV": "2024-05-28",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "1",
      "Control_Type": "ACTIVE C49649",
      "STUDYID": "ARGX-113-2007",
      "Investigational_Treatment": "HYALURONIDASE (HUMAN RECOMBINANT) 743QUY4VD8",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 5,
      "days_since_last_ae_refresh": 41,
      "days_between": 36,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "iim",
      "study": "argx-113-2011",
      "sdtm_ae_refresh_date": "2024-06-26",
      "adsl_refresh_date": "2024-06-26",
      "Trial_Title": "A PHASE 3, SINGLE-ARM, MULTICENTER, OPEN-LABEL EXTENSION OF STUDY ARGX-113-2007 TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD PH20 SC IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHY",
      "No_of_subjects_treated": 44,
      "First_ICF_date": "2023-09-12",
      "eosdt": "2024-06-06",
      "lstcndt": "2024-06-13",
      "FPFV": "2023-09-12",
      "LPLV": "2024-06-13",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2011",
      "Investigational_Treatment": "HYALURONIDASE (HUMAN RECOMBINANT) 743QUY4VD8",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 19,
      "days_since_last_ae_refresh": 19,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "itp",
      "study": "argx-113-1803",
      "sdtm_ae_refresh_date": "2024-06-07",
      "adsl_refresh_date": "2024-06-07",
      "Trial_Title": "A PHASE 3, MULTICENTER, OPEN-LABEL, LONG-TERM TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF EFGARTIGIMOD (ARGX-113) 10 MG/KG INTRAVENOUS IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA.",
      "No_of_subjects_treated": 101,
      "First_ICF_date": "2020-06-02",
      "eosdt": "2024-04-04",
      "lstcndt": "2024-05-31",
      "FPFV": "2020-06-02",
      "LPLV": "2024-05-31",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-1803",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A Phase 3 multicenter, open-label, long-term trial to evaluate the safety and efficacy of efgartigimod (ARGX-113) 10mg/kg Intravenous in adult patients with primary immune thrombocytopenia (ADVANCE+)",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 38,
      "days_since_last_ae_refresh": 38,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": "2024-05-03",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "itp",
      "study": "argx-113-2005",
      "sdtm_ae_refresh_date": "2024-06-08",
      "adsl_refresh_date": "2024-06-08",
      "Trial_Title": "A PHASE 3, MULTICENTER, OPEN-LABEL, LONG-TERM TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF EFGARTIGIMOD (ARGX-113) PH20 SUBCUTANEOUS IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA",
      "No_of_subjects_treated": 173,
      "First_ICF_date": "2021-11-17",
      "eosdt": "2024-06-03",
      "lstcndt": "2024-06-07",
      "FPFV": "2021-11-17",
      "LPLV": "2024-06-07",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2005",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A Phase 3, Multicenter, Open-Label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX‑113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC+)",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 37,
      "days_since_last_ae_refresh": 37,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": "2024-05-04",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "ln",
      "study": "argx-113-2202",
      "sdtm_ae_refresh_date": "2024-06-29",
      "adsl_refresh_date": "2024-06-29",
      "Trial_Title": "A MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EFGARTIGIMOD IN CHINESE PATIENTS WITH LUPUS NEPHRITIS",
      "No_of_subjects_treated": 39,
      "First_ICF_date": "2023-02-21",
      "eosdt": "2024-06-14",
      "lstcndt": "2024-06-20",
      "FPFV": "2023-02-21",
      "LPLV": "2024-06-20",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.5",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ZL-1103-013",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (Zai Protocol No.: ZL-1103-013)",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 16,
      "days_since_last_ae_refresh": 16,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-2002",
      "sdtm_ae_refresh_date": "2024-06-08",
      "adsl_refresh_date": "2024-06-08",
      "Trial_Title": "A LONG-TERM, SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE 3 STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF MULTIPLE SUBCUTANEOUS INJECTIONS OF EFGARTIGIMOD PH20 SC IN",
      "No_of_subjects_treated": 180,
      "First_ICF_date": "2021-04-26",
      "eosdt": "2024-05-06",
      "lstcndt": "2024-06-04",
      "FPFV": "2021-04-26",
      "LPLV": "2024-06-04",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2002",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Extension Study of ARGX-113-2001 to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients with Generalized Myasthenia Gravis",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 37,
      "days_since_last_ae_refresh": 37,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-2003",
      "sdtm_ae_refresh_date": "2024-06-11",
      "adsl_refresh_date": "2024-06-12",
      "Trial_Title": "A PHASE 3B, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE DIFFERENT DOSING REGIMENS OF INTRAVENOUS EFGARTIGIMOD TO MAXIMIZE AND MAINTAIN CLINICAL BENEFIT IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS",
      "No_of_subjects_treated": 69,
      "First_ICF_date": "2021-12-16",
      "eosdt": "2024-05-09",
      "lstcndt": "2024-06-12",
      "FPFV": "2021-12-16",
      "LPLV": "2024-06-04",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2003",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "An open-label, single arm, phase 4 trial to evaluate real world dosing to maintain clinical benefit of efgartigimod in myasthenia gravis.",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 33,
      "days_since_last_ae_refresh": 34,
      "days_between": 1,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-2006",
      "sdtm_ae_refresh_date": "2024-07-09",
      "adsl_refresh_date": "2024-07-09",
      "Trial_Title": "OPEN-LABEL UNCONTROLLED TRIAL TO EVALUATE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND ACTIVITY OF EFGARTIGIMOD IN CHILDREN FROM 2 TO LESS THAN 18 YEARS OF AGE WITH GENERALIZED MYASTHENIA GRAVIS",
      "No_of_subjects_treated": 12,
      "First_ICF_date": "2021-12-02",
      "eosdt": "2024-05-01",
      "lstcndt": "2024-05-01",
      "FPFV": "2021-10-26",
      "LPLV": "2024-05-01",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "1",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2006",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 6,
      "days_since_last_ae_refresh": 6,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-2008",
      "sdtm_ae_refresh_date": "2024-06-11",
      "adsl_refresh_date": "2024-06-11",
      "Trial_Title": "A LONG-TERM, SINGLE-ARM, OPEN-LABEL, MULTICENTER TRIAL TO EVALUATE SAFETY OF EFGARTIGIMOD ADMINISTERED INTRAVENOUSLY AND EFGARTIGIMOD PH20 ADMINISTERED SUBCUTANEOUSLY IN CHILDREN WITH GENERALIZED MYASTHENIA GRAVIS",
      "No_of_subjects_treated": 8,
      "First_ICF_date": "2022-08-18",
      "eosdt": null,
      "lstcndt": "2024-06-05",
      "FPFV": "2022-08-18",
      "LPLV": "2024-06-05",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "1",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2008",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A Long-term, Single-Arm, Open-label, Multicenter, Follow-on Trial of ARGX-113-2006 to Evaluate Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 34,
      "days_since_last_ae_refresh": 34,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-2101",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "",
      "status_ss": "",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "mn",
      "study": "argx-113-2203",
      "sdtm_ae_refresh_date": "2024-06-29",
      "adsl_refresh_date": "2024-06-29",
      "Trial_Title": "A MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EFGARTIGIMOD IN CHINESE PATIENTS WITH PRIMARY MEMBRANOUS NEPHROPATHY",
      "No_of_subjects_treated": 42,
      "First_ICF_date": "2023-02-20",
      "eosdt": "2024-06-17",
      "lstcndt": "2024-06-20",
      "FPFV": "2023-02-20",
      "LPLV": "2024-06-20",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.5",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ZL-1103-014",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Efgartigimod in Chinese Patients With Primary Membranous Nephropathy (Zai Protocol No.: ZL-1103-014)",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 16,
      "days_since_last_ae_refresh": 16,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "pemphigus",
      "study": "argx-113-1905",
      "sdtm_ae_refresh_date": "2024-06-14",
      "adsl_refresh_date": "2024-06-14",
      "Trial_Title": "AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY OF ARGX-113-1904 TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD PH20 SC IN PATIENTS WITH PEMPHIGUS (ADDRESS+)",
      "No_of_subjects_treated": 149,
      "First_ICF_date": "2021-07-15",
      "eosdt": "2024-03-25",
      "lstcndt": "2024-03-25",
      "FPFV": "2021-07-15",
      "LPLV": "2024-03-25",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-1905",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Pemphigus (ADDRESS+)",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 31,
      "days_since_last_ae_refresh": 31,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "pots",
      "study": "argx-113-2104",
      "sdtm_ae_refresh_date": "2024-06-26",
      "adsl_refresh_date": "2024-06-26",
      "Trial_Title": "A PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EFGARTIGIMOD IV IN ADULT PATIENTS WITH POST-COVID-19 POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS)",
      "No_of_subjects_treated": 53,
      "First_ICF_date": "2022-11-01",
      "eosdt": "2024-04-18",
      "lstcndt": "2024-04-18",
      "FPFV": "2022-11-01",
      "LPLV": "2024-04-18",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.5",
      "Randomization_Quotient": "0.67",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-2104",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A Phase 2 randomized, double-blind placebo-controlled trial to evaluate the efficacy, safety, and tolerability of Efgartigimod IV in adult patients with Post COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS)",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 19,
      "days_since_last_ae_refresh": 19,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "pots",
      "study": "argx-113-2105",
      "sdtm_ae_refresh_date": "2024-06-19",
      "adsl_refresh_date": "2024-06-19",
      "Trial_Title": "OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN ADULT PATIENTS WITH POST-COVID-19 POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (PC-POTS) WHO COMPLETED STUDY ARGX-113-2105",
      "No_of_subjects_treated": 33,
      "First_ICF_date": "2023-06-26",
      "eosdt": "2024-05-28",
      "lstcndt": "2024-06-06",
      "FPFV": "2023-06-26",
      "LPLV": "2024-06-06",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "1",
      "Control_Type": "NA",
      "STUDYID": "ARGX-113-2105",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "An Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 26,
      "days_since_last_ae_refresh": 26,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "sjogren",
      "study": "argx-113-2106",
      "sdtm_ae_refresh_date": "2024-06-14",
      "adsl_refresh_date": "2024-06-15",
      "Trial_Title": "A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOUBLE-BLINDED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS EFGARTIGIMOD IN ADULT PARTICIPANTS WITH PRIMARY SJO EGRENS SYNDROME",
      "No_of_subjects_treated": 34,
      "First_ICF_date": "2023-05-08",
      "eosdt": "2024-02-12",
      "lstcndt": "2024-02-12",
      "FPFV": "2023-05-08",
      "LPLV": "2024-02-12",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.67",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-2106",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A Phase 2, Randomized, Placebo-Controlled, Parallel-Group, Double-Blinded, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Intravenous Efgartigimod in Adult Participants With Primary Sjögren’s Syndrome",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 30,
      "days_since_last_ae_refresh": 31,
      "days_between": 1,
      "ord": 1,
      "ae_refresh_dt": "2024-06-12",
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "sjogren",
      "study": "argx-113-2211",
      "sdtm_ae_refresh_date": "2024-07-03",
      "adsl_refresh_date": "2024-07-03",
      "Trial_Title": "OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF EFGARTIGIMOD IN ADULT PATIENTS WITH PRIMARY SJOEGREN�S SYNDROME (PSS) WHO COMPLETE QUALIFYING EFGARTIGIMOD PSS STUDIES",
      "No_of_subjects_treated": 24,
      "First_ICF_date": "2023-11-29",
      "eosdt": "2024-05-15",
      "lstcndt": "2024-06-13",
      "FPFV": "2023-11-29",
      "LPLV": "2024-06-13",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2211",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "An Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients with primary Sjogrens Syndrome (pSS) who complete qualifying efgartigimod pSS studies",
      "status_ss": "startup",
      "days_since_last_adsl_refresh": 12,
      "days_since_last_ae_refresh": 12,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-117",
      "indication": "dgf",
      "study": "argx-117-2201",
      "sdtm_ae_refresh_date": "2024-06-27",
      "adsl_refresh_date": "2024-06-27",
      "Trial_Title": "A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, EFFICACY, AND TOLERABILITY OF ARGX-117 IN IMPROVING ALLOGRAFT FUNCTION IN RECIPIENTS OF A DECEASED DO",
      "No_of_subjects_treated": 9,
      "First_ICF_date": "2024-02-16",
      "eosdt": null,
      "lstcndt": "2024-06-14",
      "FPFV": "2023-11-29",
      "LPLV": "2024-06-14",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.5",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-117-2201",
      "Investigational_Treatment": "EMPASIPRUBART PVA73UA67L",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-\r\nControlled Study to Assess the Safety, Efficacy, and Tolerability of ARGX-117 in Improving Allograft Function in Recipients of a Deceased Donor Renal Allograft at Risk for Delayed Graft Function",
      "status_ss": "startup",
      "days_since_last_adsl_refresh": 18,
      "days_since_last_ae_refresh": 18,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-117",
      "indication": "hv",
      "study": "argx-117-2303",
      "sdtm_ae_refresh_date": "2024-06-12",
      "adsl_refresh_date": "2024-06-12",
      "Trial_Title": "A PHASE 1, OPEN-LABEL, RANDOMIZED, PARALLEL-GROUP STUDY TO ASSESS THE ABSOLUTE BIOAVAILABILITY OF EMPASIPRUBART SC IN HEALTHY PARTICIPANTS",
      "No_of_subjects_treated": 24,
      "First_ICF_date": "2024-03-11",
      "eosdt": null,
      "lstcndt": "2024-05-24",
      "FPFV": "2024-03-11",
      "LPLV": "2024-05-24",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "ACTIVE C49649",
      "STUDYID": "ARGX-117-2303",
      "Investigational_Treatment": "EMPASIPRUBART PVA73UA67L",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A Phase 1, Open-label, Randomized, Parallel-group Study to Assess the Absolute Bioavailability of Empasiprubart SC in Healthy Participants",
      "status_ss": "planning",
      "days_since_last_adsl_refresh": 33,
      "days_since_last_ae_refresh": 33,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-117",
      "indication": "mmn",
      "study": "argx-117-2002",
      "sdtm_ae_refresh_date": "2024-06-11",
      "adsl_refresh_date": "2024-06-11",
      "Trial_Title": "A PHASE 2, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY",
      "No_of_subjects_treated": 58,
      "First_ICF_date": "2022-03-31",
      "eosdt": "2024-04-24",
      "lstcndt": "2024-05-28",
      "FPFV": "2022-03-31",
      "LPLV": "2024-05-28",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": ".667",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-117-2002",
      "Investigational_Treatment": "EMPASIPRUBART PVA73UA67L",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 34,
      "days_since_last_ae_refresh": 34,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-117",
      "indication": "mmn",
      "study": "argx-117-2003",
      "sdtm_ae_refresh_date": "2024-07-02",
      "adsl_refresh_date": "2024-07-02",
      "Trial_Title": "A LONG-TERM EXTENSION OF THE ARGX-117-2002 TRIAL TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY, EFFICACY, PHARMACODYNAMICS, PHARMACOKINETICS, AND IMMUNOGENICITY OF ARGX-117 IN ADULTS WITH MULTIFOCAL MOTOR NEUROPATHY",
      "No_of_subjects_treated": 50,
      "First_ICF_date": "2023-01-18",
      "eosdt": "2023-09-26",
      "lstcndt": "2024-06-26",
      "FPFV": "2023-01-18",
      "LPLV": "2024-06-26",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "ACTIVE C49649",
      "STUDYID": "ARGX-117-2003",
      "Investigational_Treatment": "EMPASIPRUBART PVA73UA67L",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A Long Term Extension of the ARGX-117-2002 trial to Evaluate the Long-Term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults with Multifocal Motor Neuropathy",
      "status_ss": "startup",
      "days_since_last_adsl_refresh": 13,
      "days_since_last_ae_refresh": 13,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-119",
      "indication": "cms",
      "study": "argx-119-2301",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": "2024-07-15",
      "Trial_Title": "MULTICENTER, MULTINATIONAL, NATURAL HISTORY STUDY IN PARTICIPANTS WITH DOK7 CONGENITAL MYASTHENIC SYNDROMES",
      "No_of_subjects_treated": 0,
      "First_ICF_date": "2024-02-13",
      "eosdt": "2024-04-10",
      "lstcndt": "2024-06-13",
      "FPFV": "2024-02-13",
      "LPLV": "2024-06-13",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-119-NIS-2301",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "",
      "status_ss": "",
      "days_since_last_adsl_refresh": 0,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-119",
      "indication": "hv",
      "study": "argx-119-2201",
      "sdtm_ae_refresh_date": "2024-06-21",
      "adsl_refresh_date": "2024-06-21",
      "Trial_Title": "A PHASE 1, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF SINGLE AND MULTIPLE ASCENDING DOSES OF ARGX-119 IN HEALTHY PARTICIPANTS",
      "No_of_subjects_treated": 112,
      "First_ICF_date": "2023-02-03",
      "eosdt": "2024-06-07",
      "lstcndt": "2024-06-12",
      "FPFV": "2023-02-03",
      "LPLV": "2024-06-12",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.74",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-119-2201",
      "Investigational_Treatment": "NAV",
      "Investigational_Treatment2": "",
      "status": "ongoing",
      "Protocol_name": "A Phase 1, Randomized, Double Blinded, Placebo Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX 119 in Healthy Participants",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 24,
      "days_since_last_ae_refresh": 24,
      "days_between": 0,
      "ord": 1,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "aav",
      "study": "argx-113-2212",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "A PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EFGARTIGIMOD IN ADULT PATIENTS WITH ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) ASSOCIATED VASCULITIS (AAV)",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "status": "planning",
      "Protocol_name": "A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod in adult patients with Anti-neutrophil cytoplasmic antibody (ANCA) Associated Vasculitis (AAV)",
      "status_ss": "planning",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 2,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "aav",
      "study": "argx-113-2213",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF EFGARTIGIMOD IN ADULT PATIENTS WITH ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) ASSOCIATED VASCULITIS (AAV) WHO COMPLETED STUDY ARGX 113-2212",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "status": "planning",
      "Protocol_name": "An Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients with Anti-neutrophil cytoplasmic antibody (ANCA) Associated Vasculitis (AAV) who completed Study ARGX 113-2212",
      "status_ss": "planning",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 2,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-2102",
      "sdtm_ae_refresh_date": "2023-04-13",
      "adsl_refresh_date": "2023-07-10",
      "Trial_Title": "A RANDOMIZED, OPEN-LABEL, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE IMMUNE RESPONSE TO THE POLYVALENT PNEUMOCOCCAL VACCINE (PNEUMOVAX 23) IN HEALTHY PARTICIPANTS RECEIVING INTRAVENOUS EFGARTIGIMOD OR PLACEBO",
      "No_of_subjects_treated": 36,
      "First_ICF_date": "2021-11-17",
      "eosdt": "2022-03-08",
      "lstcndt": "2022-03-08",
      "FPFV": "2021-11-17",
      "LPLV": "2022-03-08",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.67",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-2102",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "FINAL",
      "Protocol_name": "A Randomized, Open-label, Placebo-Controlled, Parallel-Group Study to Evaluate the Immune Response to the Polyvalent Pneumococcal Vaccine (PNEUMOVAX 23) in Healthy Participants Receiving Intravenous Efgartigimod or Placebo",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 371,
      "days_since_last_ae_refresh": 459,
      "days_between": 88,
      "ord": 2,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "itp",
      "study": "argx-113-2004",
      "sdtm_ae_refresh_date": "2024-01-31",
      "adsl_refresh_date": "2024-06-20",
      "Trial_Title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND THE SAFETY OF EFGARTIGIMOD (ARGX-113) PH20 SUBCUTANEOUS IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA",
      "No_of_subjects_treated": 207,
      "First_ICF_date": "2020-12-16",
      "eosdt": "2023-10-09",
      "lstcndt": "2023-10-09",
      "FPFV": "2020-12-16",
      "LPLV": "2023-10-09",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.67",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-2004",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "FINAL",
      "Protocol_name": "A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo‑Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC)",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 25,
      "days_since_last_ae_refresh": 166,
      "days_between": 141,
      "ord": 2,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-2308",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 3, CROSSOVER TRIAL EVALUATING THE EFFICACY AND SAFETY OF EFGARTIGIMOD PH20 SC IN ADULT PARTICIPANTS WITH ACETYLCHOLINE RECEPTOR BINDING ANTIBODY (ACHR-AB) NEGATIVE GENERALIZED MYASTHENIA GRAVIS (GMG)",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "status": "planning",
      "Protocol_name": "A randomized, double-blinded, placebo-controlled, phase 3, crossover trial evaluating the efficacy and safety of efgartigimod PH20 SC in adult participants with acetylcholine receptor binding antibody (AChR-Ab) negative generalized myasthenia gravis (gMG)",
      "status_ss": "planning",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 2,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-2315",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 3, PARALLEL GROUP DESIGN STUDY EVALUATING THE EFFICACY AND SAFETY OF EFGARTIGIMOD IV  IN ADULT PARTICIPANTS WITH OCULAR MYASTHENIA GRAVIS (OMG).",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "status": "planning",
      "Protocol_name": "A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV  in adult participants with ocular myasthenia gravis (oMG).",
      "status_ss": "planning",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 2,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "pemphigus",
      "study": "argx-113-1904",
      "sdtm_ae_refresh_date": "2024-06-14",
      "adsl_refresh_date": "2024-06-14",
      "Trial_Title": "A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF EFGARTIGIMOD PH20 SC IN ADULT PATIENTS WITH PEMPHIGUS (VULGARIS OR FOLIACEUS) (ADDRESS).",
      "No_of_subjects_treated": 222,
      "First_ICF_date": "2020-12-14",
      "eosdt": "2023-08-22",
      "lstcndt": "2023-10-16",
      "FPFV": "2020-12-14",
      "LPLV": "2023-08-22",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-1904",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "FINAL",
      "Protocol_name": "A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus) (ADDRESS)",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 31,
      "days_since_last_ae_refresh": 31,
      "days_between": 0,
      "ord": 2,
      "ae_refresh_dt": null,
      "check_dshb": "Y",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "ted",
      "study": "argx-113-2301",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "A PHASE 3, RANDOMIZED,  DOUBLE-BLINDED, PLACEBO-CONTROLLED,  MULTICENTER  STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, DURABILITY, PHARMACODYNAMICS, PHARMACOKINETICS, AND IMMUNOGENICITY OF EFGARTIGIMOD  PH20 SC ADMINISTERED BY PREFILLED SYRINGE (PFS)  IN ADULT PARTICIPANTS WITH ACTIVE THYROID EYE DISEASE",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "status": "startup",
      "Protocol_name": "A Phase 3, Randomized,  Double-blinded, Placebo-Controlled,  Multicenter  Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod  PH20 SC administered by prefilled syringe (PFS)  in Adult Participants With Active Thyroid Eye Disease",
      "status_ss": "startup",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 2,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "ted",
      "study": "argx-113-2309",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": "2024-07-15",
      "Trial_Title": "A PHASE 3, RANDOMIZED,  DOUBLE-BLINDED, PLACEBO-CONTROLLED,  MULTICENTER  STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, DURABILITY, PHARMACODYNAMICS, PHARMACOKINETICS, AND IMMUNOGENICITY OF EFGARTIGIMOD  PH20 SC ADMINISTERED BY PREFILLED SYRINGE (PFS)  IN ADULT PARTICIPANTS WITH ACTIVE THYROID EYE DISEASE",
      "No_of_subjects_treated": 0,
      "First_ICF_date": "2024-06-13",
      "eosdt": null,
      "lstcndt": "2024-07-01",
      "FPFV": "2024-06-13",
      "LPLV": "2024-07-01",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "ARGX-113-2301_2309",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "status": "startup",
      "Protocol_name": "A Phase 3, Randomized,  Double-blinded, Placebo-Controlled,  Multicenter  Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod  PH20 SC administered by prefilled syringe (PFS)  in Adult Participants With Active Thyroid Eye Disease",
      "status_ss": "startup",
      "days_since_last_adsl_refresh": 0,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 2,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "ted",
      "study": "argx-113-2310",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "AN OPEN-LABEL EXTENSION, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD PH20 SC ADMINISTERED BY PREFILLED SYRINGE (PFS) IN ADULT PARTICIPANTS WITH THYROID EYE DISEASE (TED)",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "status": "planning",
      "Protocol_name": "An Open-Label Extension, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in adult participants with Thyroid Eye Disease (TED)",
      "status_ss": "planning",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 2,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-117",
      "indication": "covid-19",
      "study": "argx-117-2001",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "A FIRST-IN-HUMAN STUDY IN ADULT SUBJECTS HOSPITALIZED WITH COVID-19 INFECTION TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, IMMUNOGENICITY, AND EFFICACY OF ARGX-117",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "status": "stopped",
      "Protocol_name": "A First-in-Human Study in Adult Subjects Hospitalized with COVID-19 infection to investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of ARGX-117",
      "status_ss": "stopped",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 2,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-117",
      "indication": "dm",
      "study": "argx-117-2301",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF EMPASIPRUBART (ARGX-117) IN PATIENTS WITH DERMATOMYOSITIS",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "status": "planning",
      "Protocol_name": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of empasiprubart (ARGX-117) in Patients with Dermatomyositis",
      "status_ss": "planning",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 2,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-117",
      "indication": "mmn",
      "study": "argx-117-2202",
      "sdtm_ae_refresh_date": "2024-02-24",
      "adsl_refresh_date": "2024-06-08",
      "Trial_Title": "A MULTICENTER PROSPECTIVE LONGITUDINAL STUDY OF CLINICAL OUTCOMES, DISEASE COURSE, HEALTH-RELATED QUALITY OF LIFE, AND HEALTH CARE RESOURCE UTILIZATION IN ADULT PATIENTS WITH MULTIFOCAL MOTOR NEUROPATHY",
      "No_of_subjects_treated": 0,
      "First_ICF_date": "2023-11-29",
      "eosdt": null,
      "lstcndt": "2024-06-03",
      "FPFV": "2023-11-29",
      "LPLV": "2024-06-03",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-117-2202",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "status": "startup",
      "Protocol_name": "A Multicenter Prospective Longitudinal Study of Clinical Outcomes, Disease Course, Health- Related Quality of Life, and Health Care Resource Utilization in Adult Patients with Multifocal Motor Neuropathy",
      "status_ss": "startup",
      "days_since_last_adsl_refresh": 37,
      "days_since_last_ae_refresh": 142,
      "days_between": 105,
      "ord": 2,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-119",
      "indication": "als",
      "study": "argx-119-2303",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "PHASE 1B DOUBLE BLINDED RANDOMIZED CONTROLLED STUDY OF ARGX-119 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "status": "planning",
      "Protocol_name": "Phase 1b Double Blinded Randomized Controlled Study of ARGX-119 in Patients with Amyotrophic Lateral Sclerosis",
      "status_ss": "planning",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 2,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-119",
      "indication": "cms",
      "study": "argx-119-2302",
      "sdtm_ae_refresh_date": null,
      "adsl_refresh_date": null,
      "Trial_Title": "A PHASE 1B, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF ARGX -119 IN PARTICIPANTS WITH DOK7-CONGENITAL MYASTHENIC SYNDROMES",
      "No_of_subjects_treated": null,
      "First_ICF_date": "",
      "eosdt": null,
      "lstcndt": null,
      "FPFV": "",
      "LPLV": "",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "",
      "STUDYID": "",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "status": "planning",
      "Protocol_name": "A phase 1b, randomized, double-blinded, placebo-controlled study of ARGX -119 in participants with DOK7-congenital myasthenic syndromes",
      "status_ss": "planning",
      "days_since_last_adsl_refresh": null,
      "days_since_last_ae_refresh": null,
      "days_between": null,
      "ord": 2,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "cidp",
      "study": "argx-113-1802",
      "sdtm_ae_refresh_date": "2024-03-20",
      "adsl_refresh_date": "2024-03-20",
      "Trial_Title": "A PHASE 2 TRIAL TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF EFGARTIGIMOD PH20 SC IN ADULT PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)",
      "No_of_subjects_treated": 322,
      "First_ICF_date": "2020-04-15",
      "eosdt": "2023-05-11",
      "lstcndt": "2023-05-23",
      "FPFV": "2020-04-15",
      "LPLV": "2023-05-11",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.5",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-1802",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "final",
      "Protocol_name": "A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (ADHERE)",
      "status_ss": "completed",
      "days_since_last_adsl_refresh": 117,
      "days_since_last_ae_refresh": 117,
      "days_between": 0,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-1501",
      "sdtm_ae_refresh_date": "2021-12-17",
      "adsl_refresh_date": "2023-07-28",
      "Trial_Title": "A PAHSE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING INTRAVENOUS DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND IMMUNOGENICITY OF ARGX-113 IN HEALTHY MALES AND FEMALE SUBJECTS OF NON-CHILD BEARING POTENTIAL.",
      "No_of_subjects_treated": 62,
      "First_ICF_date": "2015-09-30",
      "eosdt": "2016-10-14",
      "lstcndt": "2016-10-14",
      "FPFV": "2015-09-30",
      "LPLV": "2016-10-14",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-1501",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "final",
      "Protocol_name": "A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Intravenous Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ARGX-113 in Healthy Males and Female Subjects of Non-Child Bearing Potential",
      "status_ss": "completed",
      "days_since_last_adsl_refresh": 353,
      "days_since_last_ae_refresh": 941,
      "days_between": 588,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-1702",
      "sdtm_ae_refresh_date": "2022-02-03",
      "adsl_refresh_date": "2023-07-28",
      "Trial_Title": "A RANDOMIZED, OPEN-LABEL,PARALLEL GROUP STUDY TO COMPARE THE PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY AND TOLERABILITY OF A SUBCUTANEOUS FORMULATION WITH AN INTRAVENOUS FORMULATION OF ARGX-113 IN HEALTHY MALE SUBJECTS",
      "No_of_subjects_treated": 40,
      "First_ICF_date": "2017-10-27T11:10",
      "eosdt": "2018-09-19",
      "lstcndt": "2018-09-19",
      "FPFV": "2017-10-16T11:35",
      "LPLV": "2018-09-19",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "",
      "Control_Type": "ACTIVE",
      "STUDYID": "ARGX-113-1702",
      "Investigational_Treatment": "",
      "Investigational_Treatment2": "",
      "status": "final",
      "Protocol_name": "A randomized, open-label, parallel group study to compare the pharmacokinetics, pharmacodynamics and safety of a subcutaneous formulation with an intravenous formulation of ARGX-113 in healthy male subjects",
      "status_ss": "completed",
      "days_since_last_adsl_refresh": 353,
      "days_since_last_ae_refresh": 893,
      "days_between": 540,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-1901",
      "sdtm_ae_refresh_date": "2022-07-01",
      "adsl_refresh_date": "2023-07-28",
      "Trial_Title": "A PHASE 1, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP TRIAL TO INVESTIGATE THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF DIFFERENT SINGLE SUBCUTANEOUS DOSE LEVELS OF EFGARTIGIMOD CO-ADMINISTERED WITH RHUPH20 IN HEALTHY ADULT MALE SUBJECTS",
      "No_of_subjects_treated": 33,
      "First_ICF_date": "2019-07-01",
      "eosdt": "2019-10-04",
      "lstcndt": "2019-10-04",
      "FPFV": "2019-07-01",
      "LPLV": "2019-10-04",
      "SDTM_IG_Version": "3.2",
      "SDTM_Version": "1.4",
      "Randomization_Quotient": "1.00",
      "Control_Type": "DOSE RESPONSE C120841",
      "STUDYID": "ARGX-113-1901",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "HYALURONIDASE (HUMAN RECOMBINANT) 743QUY4VD8",
      "status": "final",
      "Protocol_name": "A Phase 1, Randomized, Open-label, Parallel-group Trial to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Different Single Subcutaneous Dose Levels of Efgartigimod Co-administered with rHuPH20 in Healthy Adult Male Subjects",
      "status_ss": "completed",
      "days_since_last_adsl_refresh": 353,
      "days_since_last_ae_refresh": 745,
      "days_between": 392,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-1907",
      "sdtm_ae_refresh_date": "2022-07-01",
      "adsl_refresh_date": "2023-07-28",
      "Trial_Title": "A PHASE 1, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY TO COMPARE THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF MULTIPLE INTRAVENOUS INFUSIONS OF EFGARTIGIMOD WITH MULTIPLE SUBCUTANEOUS INJECTIONS OF EFGARTIGIMOD PH20 SC IN HEALTHY SUBJECTS",
      "No_of_subjects_treated": 54,
      "First_ICF_date": "2020-08-18",
      "eosdt": "2021-02-11",
      "lstcndt": "2021-02-12",
      "FPFV": "2020-08-18",
      "LPLV": "2021-02-11",
      "SDTM_IG_Version": "3.2",
      "SDTM_Version": "1.4",
      "Randomization_Quotient": "1",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-1907",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "final",
      "Protocol_name": "A Phase 1, Randomized, Open-Label, Parallel-Group Study to Compare Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Multiple Intravenous Infusions of Efgartigimod with Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Healthy Subjects.",
      "status_ss": "completed",
      "days_since_last_adsl_refresh": 353,
      "days_since_last_ae_refresh": 745,
      "days_between": 392,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-z005",
      "sdtm_ae_refresh_date": "2022-12-16",
      "adsl_refresh_date": "2023-07-28",
      "Trial_Title": "A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE 1 STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF AN INTRAVENOUS FORMULATION OF EFGARTIGIMOD IN HEALTHY C HINESE ADULT SUBJECTS",
      "No_of_subjects_treated": 16,
      "First_ICF_date": "2021-09-22",
      "eosdt": "2021-12-25",
      "lstcndt": "2021-12-25",
      "FPFV": "2021-09-22",
      "LPLV": "2021-12-25",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "0.75",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ZL-1103-005",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "final",
      "Protocol_name": "A Randomized, Double-Blinded, Placebo-Controlled Phase 1 Study to   Investigate the Pharmacokinetics, Pharmacodynamics, Safety and    Tolerability of an Intravenous Formulation of Efgartigimod in Healthy Chinese Adult Subjects (Zai Protocol ZL-1103-005)",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 353,
      "days_since_last_ae_refresh": 577,
      "days_between": 224,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "hv",
      "study": "argx-113-z006",
      "sdtm_ae_refresh_date": "2022-12-16",
      "adsl_refresh_date": "2023-07-28",
      "Trial_Title": "A RANDOMIZED, DOUBLE-BLINDED AND PLACEBO-CONTROLLED PHASE 1 STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF EFGARTIGIMOD SC CO-FORMULATED WITH RHUPH20 IN HEALTH Y CHINESE ADULT SUBJECTS",
      "No_of_subjects_treated": 16,
      "First_ICF_date": "2021-09-15",
      "eosdt": "2021-12-09",
      "lstcndt": "2021-12-27",
      "FPFV": "2021-09-15",
      "LPLV": "2021-12-27",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "0.75",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ZL-1103-006",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "final",
      "Protocol_name": "A Randomized, Double-Blinded and Placebo-Controlled Phase 1 Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Efgartigimod SC Co-formulated with rHuPH20 in Healthy Chinese Adult Subjects (Zai Protocol ZL-1103-006)",
      "status_ss": "ongoing",
      "days_since_last_adsl_refresh": 353,
      "days_since_last_ae_refresh": 577,
      "days_between": 224,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "itp",
      "study": "argx-113-1603",
      "sdtm_ae_refresh_date": "2022-08-17",
      "adsl_refresh_date": "2023-07-28",
      "Trial_Title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ARGX-113 IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA",
      "No_of_subjects_treated": 38,
      "First_ICF_date": "2017-03-14",
      "eosdt": "2018-05-31",
      "lstcndt": "2019-04-09",
      "FPFV": "2017-03-20",
      "LPLV": "2019-04-09",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "0.6",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-1603",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "final",
      "Protocol_name": "A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of ARGX-113 in Patients with Primary Immune Thrombocytopenia, followed by an Open-Label Treatment Period",
      "status_ss": "completed",
      "days_since_last_adsl_refresh": 353,
      "days_since_last_ae_refresh": 698,
      "days_between": 345,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "itp",
      "study": "argx-113-1801",
      "sdtm_ae_refresh_date": "2023-12-18",
      "adsl_refresh_date": "2024-06-21",
      "Trial_Title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF EFGARTIGIMOD (ARGX-113) 10 MG/KG INTRAVENOUS IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA.",
      "No_of_subjects_treated": 131,
      "First_ICF_date": "2019-12-09",
      "eosdt": "2022-02-03",
      "lstcndt": "2022-02-03",
      "FPFV": "2019-12-09",
      "LPLV": "2022-02-03",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "0.33",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-1801",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "final",
      "Protocol_name": "A Phase 3 multicentre, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of efgartigimod (ARGX-113) 10 mg/kg Intravenous in adult patients with primary immune thrombocytopenia (ADVANCE)",
      "status_ss": "completed",
      "days_since_last_adsl_refresh": 24,
      "days_since_last_ae_refresh": 210,
      "days_between": 186,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-1602",
      "sdtm_ae_refresh_date": "2021-01-12",
      "adsl_refresh_date": "2023-07-28",
      "Trial_Title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ARGX-113 IN PATIENTS WITH MYASTHENIA GRAVIS WHO HAVE GENERALIZED MUSCLE WEAKNESS",
      "No_of_subjects_treated": 24,
      "First_ICF_date": "2016-12-30",
      "eosdt": "2017-10-20",
      "lstcndt": "2017-10-20",
      "FPFV": "2017-01-10",
      "LPLV": "2017-10-20",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "0.5",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-1602",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "final",
      "Protocol_name": "A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of intravenous doses of ARGX-113 in patients with generalized myasthenia gravis who have moderate muscle weakness despite treatment with immunosuppressants",
      "status_ss": "completed",
      "days_since_last_adsl_refresh": 353,
      "days_since_last_ae_refresh": 1280,
      "days_between": 927,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-1704",
      "sdtm_ae_refresh_date": "2021-12-17",
      "adsl_refresh_date": "2024-04-06",
      "Trial_Title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 3 TRIAL TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ARGX-113 IN PATIENTS WITH MYASTHENIA GRAVIS HAVING GENERALIZED MUSCLE WEA KNESS",
      "No_of_subjects_treated": 167,
      "First_ICF_date": "2018-08-22",
      "eosdt": "2020-04-06",
      "lstcndt": "2020-04-06",
      "FPFV": "2018-08-22",
      "LPLV": "2020-04-06",
      "SDTM_IG_Version": "",
      "SDTM_Version": "",
      "Randomization_Quotient": "0.5",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-113-1704",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "final",
      "Protocol_name": "A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis Having Generalized Muscle Weakness (ADAPT)",
      "status_ss": "completed",
      "days_since_last_adsl_refresh": 100,
      "days_since_last_ae_refresh": 941,
      "days_between": 841,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-1705",
      "sdtm_ae_refresh_date": "2023-04-14",
      "adsl_refresh_date": "2023-07-10",
      "Trial_Title": "A LONG-TERM, SINGLE-ARM, OPEN-LABEL, MULTICENTER, PHASE 3 FOLLOW-ON TRIAL OF ARGX-113-1704 TO EVALUATE THE SAFETY AND TOLERABILITY OF ARGX-113 IN PATIENTS WITH MYASTHENIA GRAVIS HAVING GENERALIZED MUS CLE WEAKNESS",
      "No_of_subjects_treated": 145,
      "First_ICF_date": "2019-03-01",
      "eosdt": "2022-06-30",
      "lstcndt": "2022-07-20",
      "FPFV": "2019-03-01",
      "LPLV": "2022-06-30",
      "SDTM_IG_Version": "3.2",
      "SDTM_Version": "1.4",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-1705",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "final",
      "Protocol_name": "A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of\r\nARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis having Generalized Muscle Weakness (ADAPT+)",
      "status_ss": "completed",
      "days_since_last_adsl_refresh": 371,
      "days_since_last_ae_refresh": 458,
      "days_between": 87,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "mg",
      "study": "argx-113-2001",
      "sdtm_ae_refresh_date": "2023-02-20",
      "adsl_refresh_date": "2023-09-21",
      "Trial_Title": "A PHASE 3, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY TO COMPARE THE PHARMACODYNAMICS, PHARMACOKINETICS, EFFICACY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE SUBCUTANEOUS INJECTIONS OF EFGARTIGIMOD PH20 SC WITH MULTIPLE INTRAVENOUS INFUSIONS OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS",
      "No_of_subjects_treated": 110,
      "First_ICF_date": "2021-02-24",
      "eosdt": "2021-12-13",
      "lstcndt": "2022-01-20",
      "FPFV": "2021-02-05",
      "LPLV": "2021-12-13",
      "SDTM_IG_Version": "3.3",
      "SDTM_Version": "1.7",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-2001",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "final",
      "Protocol_name": "A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of Efgartigimod PH20 SC with Multiple Intravenous Infusions of Efgartigimod in Patients with Generalized Myasthenia Gravis",
      "status_ss": "completed",
      "days_since_last_adsl_refresh": 298,
      "days_since_last_ae_refresh": 511,
      "days_between": 213,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-113",
      "indication": "pemphigus",
      "study": "argx-113-1701",
      "sdtm_ae_refresh_date": "2024-02-27",
      "adsl_refresh_date": "2023-07-28",
      "Trial_Title": "AN OPEN-LABEL, NON-CONTROLLED, PHASE II STUDY TO EVALUATE THE SAFETY, PHARMACODYNAMICS, PHARMACOKINETICS, EFFICACY AND CONDITIONS OF USE OF ARGX-113 IN PATIENTS WITH MILD TO MODERATE PEMPHIGUS (VULGARIS OR FOLIACEUS)",
      "No_of_subjects_treated": 34,
      "First_ICF_date": "2017-11-02",
      "eosdt": "2020-10-28",
      "lstcndt": "2020-10-28",
      "FPFV": "2017-11-02",
      "LPLV": "2020-10-28",
      "SDTM_IG_Version": "3.2",
      "SDTM_Version": "1.4",
      "Randomization_Quotient": "",
      "Control_Type": "NONE C41132",
      "STUDYID": "ARGX-113-1701",
      "Investigational_Treatment": "EFGARTIGIMOD ALFA 961YV2O515",
      "Investigational_Treatment2": "",
      "status": "final",
      "Protocol_name": "An Open-label, Non-controlled, Phase II Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Efficacy and Conditions of Use of ARGX-113 in Patients with Mild to Moderate Pemphigus (Vulgaris or Foliaceus)",
      "status_ss": "COMPLETED",
      "days_since_last_adsl_refresh": 353,
      "days_since_last_ae_refresh": 139,
      "days_between": -214,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    },
    {
      "product": "argx-117",
      "indication": "hv",
      "study": "argx-117-1901",
      "sdtm_ae_refresh_date": "2022-12-15",
      "adsl_refresh_date": "2024-02-29",
      "Trial_Title": "A FIRST-IN-HUMAN, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL IN HEALTHY SUBJECTS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF SINGLE AND MULTIPLE ASCENDING INTRAVENOUS DOSE LEVELS OF ARGX-117 AND SUBCUTANEOUS DOSE LEVELS OF ARGX-117 CO-MIXED WITH RECOMBINANT HUMAN HYALURONIDASE PH20",
      "No_of_subjects_treated": 109,
      "First_ICF_date": "2020-03-10",
      "eosdt": "2022-08-26",
      "lstcndt": "2022-08-26",
      "FPFV": "2020-03-10",
      "LPLV": "2022-08-26",
      "SDTM_IG_Version": "3.2",
      "SDTM_Version": "1.4",
      "Randomization_Quotient": "0.75",
      "Control_Type": "PLACEBO C49648",
      "STUDYID": "ARGX-117-1901",
      "Investigational_Treatment": "NAV",
      "Investigational_Treatment2": "",
      "status": "final",
      "Protocol_name": "A First-In-Human, Randomized, Double-Blinded, Placebo-Controlled Trial in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Ascending Intravenous and Subcutaneous Doses of ARGX-117",
      "status_ss": "completed",
      "days_since_last_adsl_refresh": 137,
      "days_since_last_ae_refresh": 578,
      "days_between": 441,
      "ord": 3,
      "ae_refresh_dt": null,
      "check_dshb": "",
      "EDC_extract_dt": null,
      "EDC_extract_min_dt": null
    }
  ]
}
